2186 — Luye Pharma Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$9.26bn
- HK$12.85bn
- CNY6.14bn
- 39
- 70
- 15
- 32
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | ARS | ARS | ARS | ARS | |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | 1,634 | 942 | -74.6 | 670 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 202 | 371 | 661 | 455 | — |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -869 | -791 | -986 | -142 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1,423 | 1,033 | 182 | 1,654 | — |
Capital Expenditures | -3,051 | -1,520 | -1,542 | -1,164 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 422 | 1,658 | -1,894 | -495 | — |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2,629 | 138 | -3,436 | -1,658 | — |
Financing Cash Flow Items | -97.9 | -933 | 1,241 | 720 | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1,844 | 254 | 1,879 | 54.1 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 630 | 1,538 | -1,427 | -115 | — |